Korean Fermented Paste Gochujang Cuts Colorectal Tumors by Rewiring Cell Metabolism

Gochujang, the fermented Korean chili paste found in everything from bibimbap to supermarket shelves, may do more than add heat to a dish. Early-stage mouse research published in the Journal of Functional Foods in July 2026 suggests the paste can significantly reduce colorectal cancer tumor burden by reprogramming how colon cells handle energy, not by rebuilding the gut microbiome as many researchers expected.

Gochujang Reduced Tumor Numbers and Restored Colon Structure in AOM/DSS Mice

The study, led by Jin Young Baek and colleagues, used a well-established carcinogen model to trigger colorectal cancer (CRC) in BALB/c mice. Azoxymethane (AOM) was injected first to initiate tumor formation; dextran sodium sulfate (DSS) was then administered in drinking water to promote inflammation and accelerate cancer progression. This AOM/DSS combination is one of the most widely used approaches in CRC animal research because it closely mirrors the inflammation-driven pathway seen in human disease.

Mice that received oral gochujang at 0.6 g/kg showed significantly fewer tumors than untreated CRC controls. Their colons were longer, heavier relative to length, and histologically healthier, with restored crypt architecture, intact epithelial structure, and reduced tissue edema. Liver and spleen weights, along with serum markers of liver stress (AST and ALT), stayed within normal ranges, indicating no systemic toxicity from the paste.

Why Colorectal Cancer Rates Are Rising, Especially in Young Koreans

Colorectal cancer is the third most commonly diagnosed cancer globally and one of the leading causes of cancer death. Diet and lifestyle drive a substantial share of that risk: high red meat consumption, processed foods, alcohol, and low fiber intake all push CRC incidence upward, while plant-rich and fermented diets are associated with lower rates. Korea has seen a notable uptick in CRC among younger adults, a trend researchers partly attribute to the spread of Western-style eating patterns.

Fermented foods have attracted interest as a potential counter-force. Dietary interventions using fermented foods are being studied for their ability to modulate gut immunity and potentially improve responses to cancer therapies. Gochujang, made from fermented soybeans, red chili powder, glutinous rice, and salt, is Firmicutes-dominant (93.35% of its microbial phyla) and rich in bioactive compounds from the fermentation process.

The Mechanism: SCFA Oxidation and GPCR Signaling, Not Microbial Diversity

Here is where the findings get genuinely surprising. Short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate, are produced when gut bacteria ferment dietary fiber. Healthy colon cells burn these SCFAs for fuel through a process called oxidative phosphorylation. In CRC, that process is hijacked: cancer cells switch to aerobic glycolysis, the so-called Warburg effect, burning glucose even when oxygen is available and effectively starving normal colonocytes of their preferred energy source.

Gochujang did not restore gut microbial diversity. Alpha-diversity (a measure of species richness within a sample) and beta-diversity (overall community structure) both remained largely unchanged compared to untreated CRC mice. Measured colonic SCFA concentrations, the actual amounts of acetate, propionate, and butyrate present, also showed no significant increase. By those metrics, the paste looked inert.

But at the gene-expression level, the picture shifted entirely. Gochujang upregulated Acss1 (acyl-CoA synthetase 1) and Cpt2 (carnitine palmitoyl transferase 2), two enzymes central to SCFA oxidation, alongside increased protein levels of SCAD (short-chain acyl-CoA dehydrogenase). Simultaneously, it downregulated c-Myc and Hk-2 (hexokinase 2), key drivers of the glycolytic switch that cancer cells depend on. The paste appeared to push colon cell metabolism back toward fat-acid burning and away from the cancer-friendly glucose pathway, using whatever SCFAs were already present more efficiently rather than raising their supply.

On top of that metabolic shift, gochujang markedly upregulated three G-protein-coupled receptors: GPR41, GPR43, and GPR109A. These receptors sit on the surface of colonocytes and immune cells, and their activation by SCFAs is linked to anti-inflammatory signaling and suppression of tumor growth. GPR43, in particular, has been identified as a functional tumor suppressor whose expression is frequently lost in colorectal cancer cells, making its restoration a meaningful target. The study found strong correlations between GPCR upregulation and better colon health indicators across the board.

Tight junction proteins, the molecular rivets that hold the gut lining together, also responded. Zo-1, Occludin, and Claudin-1 gene expression all increased, suggesting gochujang helped rebuild barrier integrity that CRC typically erodes. Pro-inflammatory cytokines IL-1b, IL-6, Cox2, and iNOS fell, while the anti-inflammatory signals IL-10 and IL-4 rose.

Open Questions: No Protein Validation, No Receptor Knockouts, Mouse-Only Data

This is preliminary, mouse-only research and comes with real limitations. The metabolic story rests almost entirely on gene expression data measured by qPCR; comprehensive protein-level validation and downstream signaling measurements are absent. Direct metabolic flux analysis, using tools like a Seahorse assay to actually watch cells switch between oxidation and glycolysis in real time, was not performed. The correlation analyses between GPCR expression and tumor outcomes used relatively small sample sizes.

Critically, the study did not use receptor-deficient mice or pharmacological inhibitors to confirm that GPR41, GPR43, or GPR109A are genuinely driving the effects. Without those knockout experiments, the GPCR upregulation remains a compelling association rather than a confirmed mechanism. Microbiome-focused trials frequently run into this kind of interpretive ceiling: descriptive endpoints can point toward a mechanism without locking it down.

The DSS cycles used were also shorter than in some protocols, which may have limited how severely the microbiota was disrupted and, consequently, how much room there was to see recovery.

What Comes Next for Gochujang and Gut Cancer Research

The authors frame their results as evidence for a host-centered mechanism: gochujang's anti-cancer effects appear to work through the colon cell itself, sharpening its ability to use available SCFAs and respond to them via surface receptors, rather than through reshaping the microbial community that produces those SCFAs. If that interpretation holds up in follow-on work, it reframes how researchers might think about fermented food interventions, shifting focus from microbiome modulation toward colonocyte metabolism.

Next steps would logically include receptor knockout models to establish causation, protein-level and flux studies to confirm the metabolic switch, and eventually human pilot data. Translating microbiome and metabolic findings into public health tools is a recognized challenge in this field, and the path from a mouse model to a dietary recommendation is long. For now, the data suggest gochujang is worth investigating seriously as a functional food candidate in colorectal cancer research, not as a treatment, but as a window into how fermented foods might influence cancer biology at the cellular level.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• This study was conducted entirely in mice; results may not translate to humans.
• Funding was not disclosed, so independent verification of the research support cannot be confirmed.
• The proposed mechanism relies primarily on gene expression data, without protein-level validation of downstream signaling or direct metabolic flux measurements.
• Causal confirmation using receptor-deficient models or inhibitors was not performed, so the GPCR mechanism remains correlational.
• Sample sizes for correlation analyses were relatively small, limiting statistical confidence.

Mouse-only AOM/DSS model study with small group sizes. Reports associations between oral gochujang administration and upregulation of colonic SCFA receptor genes (Gpr41, Gpr43, Gpr109a) and metabolic shifts away from glycolysis; causation is not established, as mechanistic confirmation via receptor-deficient models was not performed. Not yet replicated in independent animal or human populations.

References

1. Jin Young Baek, Ji-Woo Kim, Do-Youn Jeong, Seungyong Hwang, Dallas R. Donohoe, Anna Han (2026). Gochujang attenuates colorectal cancer by promoting colonic SCFA utilization and GPCR expression despite limited recovery of microbial diversity. Journal of Functional Foods. https://doi.org/10.1016/j.jff.2026.107417
2. Florian Bürtin, Christina S Mullins, Michael Linnebacher (2020). Mouse models of colorectal cancer: Past, present and future perspectives. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v26.i13.1394
3. The Role of Diet and Lifestyle in Colorectal Cancer Incidence and Survival – NCBI – NIH. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399868/
4. Sylvia L. Crowder, Heather S.L. Jim, Stephanie Hogue, Tiffany L. Carson, Doratha A. Byrd (2023). Gut microbiome and cancer implications: Potential opportunities for fermented foods. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2023.188897
5. Yong Tang, Yakun Chen, Hongmei Jiang, Gregory T. Robbins, Daotai Nie (2010). G‐protein‐coupled receptor for short‐chain fatty acids suppresses colon cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.25638
6. Raul de Jesus Cano, Gissel García Menéndez (2026). Why Clinical Trials of Microbiome-Targeted Interventions Often Fail to Support Health Claims: A Commentary on Probiotics and Translational Design. Microorganisms. https://doi.org/10.3390/microorganisms14020470
7. Tiffany L. Weir (2023). Grand challenges: Actualizing the potential of the gut microbiome to address global nutrition challenges. Frontiers in Microbiomes. https://doi.org/10.3389/frmbi.2023.1146827